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gression. In the present study patients were treated with transurethral resection followed by adjuvant chemotherapy with doxorubicin or ethoglucid, or by transurethral resection alone. In 1984 the preliminary results of this trial were published. ' We reported that the control arm was closed to patient entry based on the results of an interim analysis showing a recurrence rate of 1.1 per year in the transurethral resection Only group 'Ompared to 0.34 in both adjuvant treated groups. This difference was highly significant (P <C).OOl). We now report long-term results with emphasis on time to invasion, duration of survival and death from maligdisease.
METHODS
Objectives of the study. The objectives of the study were to compare time to first recurrence, recurrence rate and incidence of progression to muscle invasion after transurethral IX?SeCtiOn alone, transurethral resection followed by intravesical doxorubicin or transurethral resection followed by intravesical ethoglucid chemotherapy. Design of the trial. Within 1 week of transurethral resection certain treatments were randomly allocated, including intravesical doxorubicin, intravesical ethoglucid and no other treatment. Doxorubicin and ethoglucid were administered weekly for 1 month and then monthly thereafter for a t o t a l of 11 months. Recurrent tumors, if observed 1 year or less &r randomization, were resected and weekly intravesical treatment was initiated. However, total duration of intravesical treatment was limited to 1 year after the first transurethral resection. Patients were followed until the first recurrence was detected after completion of 1 year of treatment in the adjuvant treated groups or until the first recurrence after 1 year of followup in the transurethral resection only group. Further treatment was at the discretion of the local investigator. All patients continued to be monitored for time to invasion and survival.
Therapeutic regimens. Doxorubicin (50 mg. diluted in 50 ml. normal saline) or ethoglucid (1.13 gm. diluted in 100 ml. sterile water) was instilled into the bladder 3 to 14 days after transurethral resection and retained for 1 hour. Nitrofurantoin (100 mg.) was given after each instillation 3 times daily for 3 days. White blood and platelet counts, and urinalysis were obtained before each chemotherapy administration. Chemotherapy was delayed until the white blood count was 4 x 109A. or greater and the platelet count was 1.5 X 109A. or greater. Chemotherapy was also delayed whenever bacterial cystitis was present until the infection was controlled. If drug induced cystitis recurred repeatedly, the drug was given in a solution of twice the usual volume.
Evaluation of therapy. Cystoscopy was repeated every 12 weeks during year 1, every 16 weeks during year 2 and every 24 weeks thereafter in patients without recurrence. All lesions visible on cystoscopy were biopsied with recurrence established only by histological examination of the biopsy material. If cytology was positive and no lesion was visible on cystoscopy, random biopsies were done. AU participants were asked to send representative unstained histological slides from all resected material for central pathology review.
Criteria of evaluation. Time to first recurrence was defined as the time from randomization until the first cystoscopy at which recurrence was observed. Recurrence rate per year was defined relative only to cystoscopy performed before the patient was removed from the study, using the formula, number of positive cystoscopiedthe period (expressed in years) between randomization and the last cystoscopy performed while the patient remained in the study. Increase in T category was defined as progression to stage "2 disease or worse. Patients without progression were censored at the last followup cystoscopy. Survival was defined from the date of randomization until death. Patients still alive or lost to followup were censored at the last date they were known to be alive. Median duration of followup for an event is the duration of followup, such that half of the patients had been followed for a period shorter than the median and half had been followed for a period longer than the median.
Statistical methods. Time to event curves (first recurrence and survival) were estimated using the Kaplan-Meier technique2 and compared using the log rank test.3 For ordered categories with more than 2 levels a log rank test for trend was used. Differences in recurrence rates were tested using a -nonparametric permutation test. ( t r a n s u r e W resection only) was closed to patient entry based on interim analysis after 206 patients had been entered,' fewer patients were randomized to the control group.
Unknown 8 (4) 5 (3)

RESULTS
Selection
A total of 425 patients was eligible for study with followup data available on recurrence for 392 and survival for 423 (tables 1 to 3). Table 4 shows the distribution of eligible patienta by treatment group, initial T category, grade of malignancy, number of tumors present, size of tumors, previous treatment, and stratification for primary and recurrent tumors. In all treatment arms 68% of the cases were newly diagnosed at the time of trial entry and the others were recurrent Ta or T1 tumors. Median followup was 3.4 years for recurrence, 5 for invasion, 7.2 for time to death from malignant disease and 10.7 (maximum followup 14) for duration of S u r v i V a l .
Time to first recurrence. Kaplan-Meier curves are shown by treatment group for all eligible patients with followup. A global comparison by treatment was highly significant (p <0.001, fig. 1 ). Paired comparisons yielded a significant difference between doxorubicin and the control group (p <0.001) and ethoglucid and the control group (p <0.001) in favor of adjuvant chemotherapy. A comparison of doxorubicin with ethoglucid yielded no significant difference (p = 0.48). These results were similar when analyzed separately for newly diagnosed (global comparison p = 0.03) and recurrent tumors (global comparison p = 0.002). The benefit of adjuvant chemotherapy was also noted for Ta (global comparison p = 0.05) and T1 (global comparison p <0.001) tumors. Thus, adjuvant chemotherapy significantly prolonged the time to first recurrence. At 3 years 48% of the patients on doxombicin (95% confidence interval 40 to 56) and 56% on ethoglucid (95% confidence i n h~a l 48 to 64) were recurrence-free. In the control group 29% of the patients had not had recurrence tients after instillation of doxorubicin, while fever and allergic skin reaction were noted in 7 of 166 after instillation of ethoglucid. Neither leukopenia nor thrombocytopenia were seen in this study. Long-term side effects, such as a shrunken bladder, were not reported by the investigators.
DISCUSSION
Numerous randomized studies have demonstrated the advantage of adjuvant intravesical treatment after transurethral resection to decrease the recurrence rate of superficial bladder cancer compared with transurethral resection alone.4-10 However, in 2 large studies adjuvant treatment revealed no benefit.", 12 The inability to demonstrate a significant difference may have been due to the patients investigated,'Z treatment schedule11 or compound used.4 In studies comparing different intravesical cytostatics none of the drugs tested was superior to another.l3.l4
In the present study long-term differences for time to first recurrence were maintained in all patients with similar results in the subgroups with primary and recurrent tumors. For all patients the absolute benefit according to the formula, % recurrence in transurethral resection arm -% recurrence in the adjuvant treated arms, is approximately 20% for doxorubicin and 27% for ethoglucid at 3 years. The recurrence rate per year in the adjuvant treatment arms decreased to 50% of that observed with transurethral resection alone and the differences were highly significant. No differences were demonstrated between doxorubicin and ethoglucid with respect to time to first recurrence or recurrence rate.
At 5 years there was a progression in T category to worse than stage T1 disease in 14.6% of the patients, distant metastases in 4.4% and death from malignant disease in 8.8%. The values are not significantly different in the 3 arms, although the number of events is too small to draw any definitive conclusions. Since treatment of patients not in the study was at the discretion of the local investigator, 70% of all those originally allocated to transurethral resection only underwent adjuvant treatment later. Thus, adjuvant prophylactic treatment can only be compared to no or delayed treatment. After a median followup for invasion of 5 years it appeared that, of the 64 patients who had progression to stage T2 disease or worse, half had progression during the protocol treatment period, while the other half had progression during followup. Earlier reports claiming success in progression-free survival with adjuvant chemotherapy were not confirmed. 15 The pathology review revealed considerable changes in pT category from stage pT1 to pTa disease. Muscle invasive tumors were missed in 4 of the 318 cases reviewed (1.25%). Changes in tumor grade occurred in both directions, although of the 308 cases reviewed 37 (12%) were upgraded to grade 3 and 72 (23.3%) to grade 2. Therefore, as postulated by Oosterlinck et al, it is necessary to obtain a uniform pathology review when subgroups based on T category or grade are analyzed.10 In a separate study including data from this study a multivariate analysis of prognostic factors showed that grade of malignancy, tumor size and prior recurrence rate are the most powerful predictors of progression to stage T2 disease or greater or death from malignant disease. Patients with more than 3 previous recurrences per year, a tumor greater than 3 cm. and grade 3 malignancy had the worst prognosis.16
CONCLUSIONS
In regard to time to first recurrence and recurrence rate per year this European Organization for Research and Treatment of Cancer Genitourinary Group phase I11 trial indicates that adjuvant chemotherapy with doxorubicin and ethoglucid according to the aforementioned schedule is superior to transurethral resection alone. The study did not show that progression in stage or survival was influenced by the treatment regimen. However, progression was rarely observed and 70% of the patients who underwent resection alone re- ceived a d j u v a n t chemotherapy a f t e r leaving the study. Thus, the comparison w a s m a d e between a d j u v a n t a n d no o r delayed a d j u v a n t t r e a t m e n t .
